RxDoctor Payments Data

Kamalakannan Desikan, MD

Interventional Cardiology · Katy, TXNPI 1427251867

Payments from drug & device makers

$7,620in general payments, 2019–2025

Across 389 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$695
  • Johnson & Johnson$650
  • Novartis$604
  • Merck$553
  • Abbott$488
  • Sanofi-aventis U.S. LLC$354
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$7,620100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,620 in reported general payments places this provider in the 35th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$485,019
Medicare patients
645
Services billed
3,798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban261$326,791
EntrestoSacubitril/Valsartan71$97,861
XareltoRivaroxaban71$91,996
FarxigaDapagliflozin Propanediol17$20,829
Repatha SureclickEvolocumab12$18,454
MultaqDronedarone Hcl13$11,472
Metoprolol Succinate557$8,933
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide97$4,874
Olmesartan Medoxomil168$4,009
Rosuvastatin Calcium265$3,905
Atorvastatin Calcium376$2,806
Valsartan99$2,737
Nebivolol Hcl34$2,278
Ranolazine ErRanolazine16$2,199
Labetalol Hcl62$2,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$315$326,791261 claims
NovartisEntresto$604$97,86171 claims
Johnson & JohnsonXarelto$650$91,99671 claims
AstraZenecaFarxiga$341$20,82917 claims
Sanofi-aventis U.S. LLCMultaq$354$11,47213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Katy

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →